Free Trial
NASDAQ:NRSN

NeuroSense Therapeutics Q4 2024 Earnings Report

NeuroSense Therapeutics logo
$1.03 -0.01 (-0.75%)
Closing price 05/2/2025 03:59 PM Eastern
Extended Trading
$1.03 +0.00 (+0.10%)
As of 05/2/2025 04:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NeuroSense Therapeutics EPS Results

Actual EPS
-$0.06
Consensus EPS
-$0.12
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

NeuroSense Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

NeuroSense Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Monday, April 7, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

NeuroSense Therapeutics' Q1 2025 earnings is scheduled for Monday, June 23, 2025

NeuroSense Therapeutics Earnings Headlines

Gold Alert: The Truth About Fort Knox Is Coming
Owning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s already performing nearly twice as well as gold this year and looks ready to go much higher. If you wait for the news to hit, you’ll already be too late.
See More NeuroSense Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NeuroSense Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NeuroSense Therapeutics and other key companies, straight to your email.

About NeuroSense Therapeutics

NeuroSense Therapeutics (NASDAQ:NRSN), a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

View NeuroSense Therapeutics Profile

More Earnings Resources from MarketBeat